Partner Therapeutics, Inc. (PTx) will receive a $35 million milestone-based Other Transaction Agreement (OTA) with the U.S. Department of Defense (DOD) to fund two clinical studies of inhaled Leukine (sargramostim, rhu-Granulocyte Macrophage-Colony Stimulating Factor “GM-CSF”) in patients with COVID-19 associated acute hypoxemia. The program will evaluate the effect of Leukine in improving clinical outcomes, including oxygenation and percent of patients intubated. The first of the tw...